Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
CAMZYOSTM is the only Health Canada approved reversible cardiac myosin inhibitor indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy of New York Heart Association...
First and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer in Canada Significant improvement in event-free survival and pathological complete response...
First adjuvant Immunotherapy for patients at high risk of disease recurrence MONTREAL, June 28, 2022 /CNW/ - Today, Bristol Myers Squibb Canada (BMS) announced Health Canada has issued a Notice of...
Dragonfly Therapeutics, Inc. ("Dragonfly") today announced the achievement of a Phase 1 clinical development milestone for the DF6002/BMS-9896415 IL-12 program. DF6002/BMS-9896415 is a monovalent...
MONTREAL, Nov. 2, 2021 /CNW/ - Today Bristol Myers Squibb Canada announces two recent Health Canada approvals for OPDIVO® (nivolumab). Unlike traditional cancer therapies that target tumours...
First new systemic therapy in more than 15 years for cancer related to asbestos exposure MONTREAL, June 2, 2021 /CNW Telbec/ - Today, Bristol Myers Squibb Canada (BMS) announced Health Canada's...
CheckMate -9LA trial results demonstrated superior overall survival versus chemotherapy, regardless of PD-L1 expression or tumor histology1 MONTREAL, Aug. 11, 2020 /CNW/ - Today, Bristol Myers Squibb ...
Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), today announced that Bristol Myers Squibb ("BMS") has licensed its fourth TriNKET™ immunotherapy drug candidate from Dragonfly. Since the...
Dragonfly expands beyond existing collaboration with Bristol Myers Squibb in oncology and autoimmune disease to develop drug candidates against multiple targets using its proprietary platform in new...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.